Months after massive Ipsen deal, BAKX Therapeutics nets more cash for its 'Thelma and Louise' approach to cancer cell death

BAKX Therapeutics emerged from stealth in a big way back in July, striking an $852 million deal with Ipsen for its lead cancer candidate …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Months af­ter mas­sive Ipsen deal, BAKX Ther­a­peu­tics nets more cash for its 'Thel­ma and Louise' ap­proach to can­cer cell death